Hotgen(SH:688068) Soochow Securities·2025-10-23 01:25Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is focusing on innovative treatments in the cardiovascular field, particularly the potential of SGC001 as a first-in-class (FIC) drug for acute myocardial infarction (AMI) [7][31]. - The company has a diversified pipeline with multiple subsidiaries engaged in innovative drug development, including SGC001, which has received IND approvals in both China and the U.S. [7][12]. - The in vitro diagnostics (IVD) business provides a stable revenue base, with a comprehensive product layout and leading-edge technology platforms [7][12]. Summary by Sections 1. Company Overview - The company, established in 2005 and listed on the Shanghai Stock Exchange in 2019, has been actively developing innovative diagnostic technologies and drug pipelines through its subsidiaries [12][15]. 2. Innovative Drug Development - SGC001 is highlighted as a significant product for AMI treatment, with promising clinical results and a strong market need for new therapies [7][31]. - The company is expanding its drug pipeline to include various therapeutic areas, including oncology and neurodegenerative diseases, leveraging its subsidiaries for differentiated drug development [7][31]. 3. IVD Business - The IVD segment is crucial for the company's revenue, with ongoing development in various diagnostic technologies and health initiatives aimed at improving public health [7][12]. - The company has established several core technology platforms that support its IVD product offerings, enhancing its competitive position in the market [7][12]. 4. Financial Projections - The company is projected to achieve revenues of 5.42 billion, 5.97 billion, and 6.67 billion yuan from 2025 to 2027, with a gradual return to profitability expected by 2027 [1][7]. - The report anticipates that the combined value of the IVD business and innovative drug pipeline could reach approximately 48 billion yuan [7][12].